Curcumin extract improves beta cell functions in obese patients with type 2 diabetes: a randomized controlled trial.

IF 4.4 2区医学 Q1 NUTRITION & DIETETICS

Nutrition Journal Pub Date : 2024-10-01 DOI:10.1186/s12937-024-01022-3

Metha Yaikwawong, Laddawan Jansarikit, Siwanon Jirawatnotai, Somlak Chuengsamarn

{"title":"Curcumin extract improves beta cell functions in obese patients with type 2 diabetes: a randomized controlled trial.","authors":"Metha Yaikwawong, Laddawan Jansarikit, Siwanon Jirawatnotai, Somlak Chuengsamarn","doi":"10.1186/s12937-024-01022-3","DOIUrl":null,"url":null,"abstract":"Background: Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin production, leading to elevated blood glucose levels. Curcumin, a polyphenolic compound from Curcuma longa, has shown potential in improving insulin sensitivity and reducing blood glucose levels, which may help mitigate type 2 diabetes progression.Objective: To assess the efficacy of improving type 2 diabetes (T2DM).Study design: This randomized, double-blind, placebo-controlled trial included subjects (n = 272) with criteria for type 2 diabetes.Methods: All subjects were randomly assigned to receive curcumin (1500 mg/day) or placebo with blind labels for 12 months. To assess the improvement of T2DM after curcumin treatments body weight and body mass index, fasting plasma glucose, glycosylated hemoglobin A1c, β-cell function (homeostasis model assessment [HOMA-β]), insulin resistance (HOMA-IR), insulin, adiponectin, and leptin were monitored at the baseline and at 3-, 6-, 9-, and 12-month visits during the course of intervention.Results: After 12 months of treatment, the curcumin-treated group showed a significant decrease in fasting blood glucose (115.49 vs.130.71; P < 0.05), HbA1c (6.12 vs. 6.47; P < 0.05). In addition, the curcumin-treated group showed a better overall function of β-cells, with higher HOMA-β (136.20 vs. 105.19; P < 0.01) The curcumin-treated group showed a lower level of HOMA-IR (4.86 vs. 6.04; P < 0.001) and higher adiponectin (14.51 vs. 10.36; P < 0.001) when compared to the placebo group. The curcumin-treated group also showed a lower level of leptin (9.42 vs. 20.66; P < 0.001). Additionally, body mass index was lowered (25.9 4 vs.29.34), with a P value of 0.001.Conclusions: A 12-month curcumin intervention in type 2 diabetes patients shows a significant glucose-lowering effect. Curcumin treatment appeared to improve the overall function of β-cells and reduce both insulin resistance and body weight, with very minor adverse effects. Curcumin intervention in obese patients with type 2 diabetes may be beneficial.Trial registration: Thai clinical trials regentrify no.20140303003.","PeriodicalId":19203,"journal":{"name":"Nutrition Journal","volume":null,"pages":null},"PeriodicalIF":4.4000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11445938/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nutrition Journal","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12937-024-01022-3","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Type 2 diabetes mellitus (T2DM) is a chronic condition characterized by insulin resistance and impaired insulin production, leading to elevated blood glucose levels. Curcumin, a polyphenolic compound from Curcuma longa, has shown potential in improving insulin sensitivity and reducing blood glucose levels, which may help mitigate type 2 diabetes progression.

Objective: To assess the efficacy of improving type 2 diabetes (T2DM).

Study design: This randomized, double-blind, placebo-controlled trial included subjects (n = 272) with criteria for type 2 diabetes.

Methods: All subjects were randomly assigned to receive curcumin (1500 mg/day) or placebo with blind labels for 12 months. To assess the improvement of T2DM after curcumin treatments body weight and body mass index, fasting plasma glucose, glycosylated hemoglobin A_1c, β-cell function (homeostasis model assessment [HOMA-β]), insulin resistance (HOMA-IR), insulin, adiponectin, and leptin were monitored at the baseline and at 3-, 6-, 9-, and 12-month visits during the course of intervention.

Results: After 12 months of treatment, the curcumin-treated group showed a significant decrease in fasting blood glucose (115.49 vs.130.71; P < 0.05), HbA_1c (6.12 vs. 6.47; P < 0.05). In addition, the curcumin-treated group showed a better overall function of β-cells, with higher HOMA-β (136.20 vs. 105.19; P < 0.01) The curcumin-treated group showed a lower level of HOMA-IR (4.86 vs. 6.04; P < 0.001) and higher adiponectin (14.51 vs. 10.36; P < 0.001) when compared to the placebo group. The curcumin-treated group also showed a lower level of leptin (9.42 vs. 20.66; P < 0.001). Additionally, body mass index was lowered (25.9 4 vs.29.34), with a P value of 0.001.

Conclusions: A 12-month curcumin intervention in type 2 diabetes patients shows a significant glucose-lowering effect. Curcumin treatment appeared to improve the overall function of β-cells and reduce both insulin resistance and body weight, with very minor adverse effects. Curcumin intervention in obese patients with type 2 diabetes may be beneficial.

Trial registration: Thai clinical trials regentrify no.20140303003.

查看原文本刊更多论文

姜黄素提取物可改善肥胖 2 型糖尿病患者的β细胞功能：随机对照试验。

背景：2 型糖尿病（T2DM）是一种慢性疾病，其特点是胰岛素抵抗和胰岛素分泌受损，从而导致血糖水平升高。姜黄素是一种从姜黄中提取的多酚化合物，已显示出改善胰岛素敏感性和降低血糖水平的潜力，这可能有助于缓解 2 型糖尿病的进展：评估改善 2 型糖尿病（T2DM）的疗效：这项随机、双盲、安慰剂对照试验纳入了符合 2 型糖尿病标准的受试者（n = 272）：所有受试者均被随机分配接受姜黄素（1500 毫克/天）或安慰剂治疗，盲标治疗 12 个月。为了评估姜黄素治疗后 T2DM 的改善情况，在基线和干预过程中的 3、6、9 和 12 个月访视时监测体重和体重指数、空腹血浆葡萄糖、糖化血红蛋白 A1c、β 细胞功能（稳态模型评估 [HOMA-β]）、胰岛素抵抗（HOMA-IR）、胰岛素、脂联素和瘦素：治疗 12 个月后，姜黄素治疗组的空腹血糖显著下降（115.49 vs. 130.71；P 1c（6.12 vs. 6.47；P 结论：姜黄素干预治疗 12 个月后，空腹血糖显著下降（115.49 vs. 130.71；P 1c（6.12 vs. 6.47；P 1c）：对 2 型糖尿病患者进行为期 12 个月的姜黄素干预具有明显的降糖效果。姜黄素治疗似乎改善了β细胞的整体功能，降低了胰岛素抵抗和体重，不良反应非常轻微。姜黄素对肥胖的2型糖尿病患者的干预可能是有益的：泰国临床试验登记号：20140303003。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nutrition Journal NUTRITION & DIETETICS-

CiteScore

9.80

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： Nutrition Journal publishes surveillance, epidemiologic, and intervention research that sheds light on i) influences (e.g., familial, environmental) on eating patterns; ii) associations between eating patterns and health, and iii) strategies to improve eating patterns among populations. The journal also welcomes manuscripts reporting on the psychometric properties (e.g., validity, reliability) and feasibility of methods (e.g., for assessing dietary intake) for human nutrition research. In addition, study protocols for controlled trials and cohort studies, with an emphasis on methods for assessing dietary exposures and outcomes as well as intervention components, will be considered. Manuscripts that consider eating patterns holistically, as opposed to solely reductionist approaches that focus on specific dietary components in isolation, are encouraged. Also encouraged are papers that take a holistic or systems perspective in attempting to understand possible compensatory and differential effects of nutrition interventions. The journal does not consider animal studies. In addition to the influence of eating patterns for human health, we also invite research providing insights into the environmental sustainability of dietary practices. Again, a holistic perspective is encouraged, for example, through the consideration of how eating patterns might maximize both human and planetary health.